Steve Closter compensation by year
Syndax Pharmaceuticals Summary Compensation Table · all 2 fiscal years held| Component | FY2024 | FY2025 |
|---|---|---|
| Salary | $364,167 | $485,300 |
| Bonus | $0 | $0 |
| Stock awards | $745,280 | $496,359 |
| Option awards | $2,222,927 | $806,650 |
| Non-equity incentive | $214,763 | $327,578 |
| Pension and deferred compensation | $0 | $0 |
| All other | $10,000 | $10,000 |
| Total | $3,557,137 | $2,125,887 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Syndax Pharmaceuticals Inc DEF 14A filed April 30, 2026, accession 0001193125-26-197859, and prior-year filings.
How this page was built: the Syndax Pharmaceuticals Inc filed document, accession 0001193125-26-197859. Every figure is read from that document and cited to the page and table it appears in. Filed April 30, 2026.
Equity holdings
unvested awards at FY2025 year-end| Type | Unvested units | Value at year-end | Exercise price |
|---|---|---|---|
| PSU | 23,400 | $491,634 | — |
| PSU | 16,667 | $350,174 | — |
| RSU | 13,500 | $283,635 | — |
| RSU | 6,000 | $126,060 | — |
| Option | 67,292 | — | $14.65 |
| Option | 84,375 | — | $21.92 |
Per the Outstanding Equity Awards at Fiscal Year-End table in Syndax Pharmaceuticals Inc's FY2025 proxy; value at the fiscal year-end close, as the company printed it.
Change-in-control & termination
estimated payments Syndax Pharmaceuticals discloses, by trigger · FY2025| Trigger | Cash severance | Accelerated equity | Benefits continuation | Total as disclosed |
|---|---|---|---|---|
| Involuntary termination without cause | $363,975 | $889,417 | $15,897 | $1,269,289 |
| Change in control and involuntary termination | $1,055,528 | $2,036,440 | $31,793 | $3,123,761 |
Per the Potential Payments Upon Termination or Change in Control table in Syndax Pharmaceuticals Inc's FY2025 proxy. Estimates as the company printed them; a dash means it printed no figure.
Syndax Pharmaceuticals’s named executive officers, FY2025
as the company reported each| Named executive officer | Role | FY2025 total |
|---|---|---|
| Michael Metzger | Chief Executive Officer | $7,089,213 |
| Nick Botwood | Head of Research and Development, Chief Medical Officer | $2,879,099 |
| Keith Goldan | Chief Financial Officer | $2,470,802 |
| Luke Albrecht | General Counsel and Secretary | $2,331,617 |
| Steve Closter · this page | Chief Commercial Officer | $2,125,887 |
Steve Closter's compensation dossier, Syndax Pharmaceuticals
You have read Steve Closter's totals and holdings. The dossier adds each equity grant Syndax Pharmaceuticals disclosed for Steve Closter and Syndax Pharmaceuticals's own disclosed peer group, where the company discloses them, with every row in a PDF and a CSV cited to its filing.
See an example →The full Syndax Pharmaceuticals compensation record
free company briefThis page is one person within Syndax Pharmaceuticals's record. The company brief lists every named executive, each linking to their own page.
Peer companies
named in the Syndax Pharmaceuticals proxy · each links to its own free briefCompensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them. Or order Syndax Pharmaceuticals's full Executive Compensation Report with peer benchmarking.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Syndax Pharmaceuticals's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.